Notice for lanadelumab (Shire Australia Pty Limited)
Active ingredients
lanadelumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the routine prevention of angioedema attacks and control of symptoms of hereditary angioedema (HAE) in adolescents and adults